高尿酸血症治療薬の世界市場レポート 2024年

高尿酸血症治療市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.3％で65億4,000万米ドルに成長します。予測期間における成長の原動力は、慢性腎臓病の有病率の上昇、早期診断の重視、個別化医療への関心の高まり、新薬製剤の創出、医療支出の増加です。この時期の主要動向としては、精密医療の重視、併用療法の増加、非侵襲的治療の進歩、薬剤の安全性と有効性の重視、薬理ゲノミクスの進展などが挙げられます。

高尿酸血症と痛風の有病率の増加は、今後の高尿酸血症治療市場の成長を牽引すると考えられます。高尿酸血症は血液中の尿酸濃度が高いことを特徴とし、関節に尿酸塩結晶が沈着することで痛みを伴う関節炎である痛風を引き起こす可能性があります。高尿酸血症や痛風の増加は、遺伝的素因、食事からのプリン体摂取量の多さ、肥満、腎機能、飲酒や脱水などのライフスタイルの選択、特定の薬剤、高血圧や糖尿病などの慢性疾患などの要因に影響されます。高尿酸血症の治療は、尿酸値を管理し、高尿酸血症や痛風の発症や進行を予防し、関連症状を緩和するために極めて重要です。例えば、Lancet誌が2024年7月に報告したところによると、痛風は2020年には女性より男性の方が3.26倍多く、加齢とともに増加し、2050年には推定9,580万人の症例が予想されています。この罹患率の上昇が高尿酸血症治療市場の成長を後押ししています。

高尿酸血症治療市場の主要企業は、患者の痛風治療へのアクセスを改善する費用対効果の高い代替品を提供するため、治療同等ジェネリック医薬品などの革新的製品の開発に注力しています。治療同等ジェネリック医薬品とは、先発医薬品と同じ有効成分を含み、同じ剤形で投与され、同様の臨床効果と安全性プロファイルが期待される医薬品です。例えば、2024年1月、インドの製薬会社Lupinは、フェブキソスタット錠（40mgと80mg）とバレニクリン錠（0.5mgと1mg）の承認を米国保健規制当局から取得しました。これらのジェネリック医薬品は、高尿酸血症治療（フェブキソスタット）と禁煙補助薬（バレニクリン）を必要とする患者に、より安価な選択肢を提供することを目的としています。Lupinは、これらのジェネリック医薬品を提供することにより、必要な医薬品へのアクセスを向上させ、米国医薬品市場でシェアを獲得し、患者さんの医療ニーズに費用対効果の高い選択肢を提供することを目指します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界の高尿酸血症治療市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の高尿酸血症治療市場の実績：規模と成長、2018～2023年
• 世界の高尿酸血症治療市場の予測：規模と成長、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の高尿酸血症治療市場：タイプ別、実績と予測、2018～2023年、2023～2028年、2033年
• 無症候性高尿酸血症
• 症状のある高尿酸血症
• その他
• 世界の高尿酸血症治療市場：薬剤別、実績と予測、2018～2023年、2023～2028年、2033年
• 非ステロイド性抗炎症薬
• キサンチンオキシダーゼ阻害剤
• 選択的尿酸再吸収阻害剤（SURI）
• 尿酸排泄促進剤
• その他
• 世界の高尿酸血症治療市場：疾患別、実績と予測、2018～2023年、2023～2028年、2033年
• 痛風
• 腎臓結石
• その他
• 世界の高尿酸血症治療市場：エンドユーザー別、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• 在宅医療
• 専門クリニック
• その他

第7章 地域別・国別分析

• 世界の高尿酸血症治療市場：地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の高尿酸血症治療市場：国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 高尿酸血症治療市場：競合情勢
• 高尿酸血症治療市場：企業プロファイル
  • Pfizer Inc.
  • Merck & Co.
  • Bayer AG
  • Sanofi SA
  • Myers Squibb Bristol Company

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline PLC
• Roche Holdings Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceuticals
• Regeneron Pharmaceuticals Inc.
• Teijin Pharma Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals Inc.
• Glenmark Pharmaceuticals Ltd.
• Kissei Pharmaceutical Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的な分析

第36章 付録

Hyperuricemia medications are used to decrease elevated uric acid levels in the blood. These treatments function by either lowering uric acid production in the body or enhancing its elimination through urine. Typically administered orally, the dosage depends on the severity of hyperuricemia, the patient's tolerance, and any underlying health issues.

There are several types of hyperuricemia drugs, asymptomatic hyperuricemia, symptomatic hyperuricemia, and others. Asymptomatic hyperuricemia refers to elevated uric acid levels without noticeable symptoms, which is usually monitored to avoid complications such as gout or kidney stones. Hyperuricemia medications include nonsteroidal anti-inflammatory drugs, xanthine oxidase inhibitors, selective uric acid reabsorption inhibitors (SURI), uricosuric agents, and others. These medications treat various conditions, such as gout and kidney stones, and are used in settings such as hospitals, homecare, specialty clinics, and more.

The hyperuricemia drugs market research report is one of a series of new reports from The Business Research Company that provides hyperuricemia drugs market statistics, including hyperuricemia drugs industry global market size, regional shares, competitors with a hyperuricemia drugs market share, detailed hyperuricemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hyperuricemia drugs industry. This hyperuricemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperuricemia drugs market size has grown strongly in recent years. It will grow from $4.39 billion in 2023 to $4.75 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The increase observed in the historical period is due to the rising incidence of gout, limited treatment options, an expanding elderly population, sedentary lifestyles, and heightened awareness of hyperuricemia.

The hyperuricemia drugs market size is expected to see strong growth in the next few years. It will grow to $6.54 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The forecast period, growth is driven by a higher prevalence of chronic kidney disease, an emphasis on early diagnosis, a growing interest in personalized medicine, the creation of new drug formulations, and a rise in healthcare spending. Key trends during this period include a greater focus on precision medicine, increased use of combination therapies, advancements in non-invasive treatments, a stronger emphasis on drug safety and efficacy, and progress in pharmacogenomics.

The increasing prevalence of hyperuricemia and gout is likely to drive the growth of the hyperuricemia drug market in the future. Hyperuricemia is characterized by high levels of uric acid in the blood, which can lead to gout, a painful arthritis caused by urate crystal deposits in the joints. The rise in hyperuricemia and gout is influenced by factors such as genetic predisposition, high purine intake from diet, obesity, kidney function, lifestyle choices such as alcohol consumption and dehydration, certain medications, and chronic conditions such as hypertension and diabetes. Drugs for hyperuricemia are crucial for managing uric acid levels, preventing the onset and progression of hyperuricemia and gout, and relieving associated symptoms. For example, The Lancet reported in July 2024 that gout was 3.26 times more common in men than women in 2020 and increased with age, with an estimated 95.8 million cases expected by 2050. This rising incidence is propelling the growth of the hyperuricemia drug market.

Major companies in the hyperuricemia drug market are concentrating on developing innovative products, such as therapeutic equivalent generic versions, to offer a cost-effective alternative that improves access to gout treatment for patients. Therapeutic equivalent generics are medications that contain the same active ingredient as brand-name drugs, are administered in the same dosage form, and are expected to have similar clinical effects and safety profiles. For example, in January 2024, Lupin, an India-based pharmaceutical company, received approval from the US health regulator for Febuxostat Tablets (40 mg and 80 mg) and Varenicline Tablets (0.5 mg and 1 mg). These generic drugs aim to provide more affordable options for patients needing hyperuricemia treatment (Febuxostat) and smoking cessation support (Varenicline). By offering these generics, Lupin seeks to enhance accessibility to essential medications, capture a share of the US pharmaceutical market, and provide patients with cost-effective alternatives for their healthcare needs.

In October 2023, Amgen Inc., a US-based pharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition is expected to enhance Amgen's ability to provide innovative therapies, especially for autoimmune and severe inflammatory diseases. Horizon Therapeutics PLC, is an Ireland-based biotechnology firm, offers anti-hyperuricemic drugs, including Krystexxa (pegloticase), which is used to treat chronic gout.

Major companies operating in the hyperuricemia drugs market are Pfizer Inc., Merck & Co., Bayer AG, Sanofi SA, Myers Squibb Bristol Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline PLC, Roche Holdings Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceuticals, Regeneron Pharmaceuticals Inc., Teijin Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Kissei Pharmaceutical Co. Ltd., Himalaya Wellness Company, Fuji Yakuhin Co. Ltd.

North America was the largest region in the hyperuricemia drugs market in 2023. The regions covered in the hyperuricemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hyperuricemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperuricemia drugs market consists of sales of allopurinol, febuxostat, probenecid, and rasburicase. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hyperuricemia Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hyperuricemia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hyperuricemia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hyperuricemia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Asymptomatic Hyperuricemia; Symptomatic Hyperuricemia; Other Types
• 2) By Drugs: Nonsteroidal Anti-Inflammatory Drugs; Xanthine Oxidase Inhibitors; Selective Uric Acid Reabsorption Inhibitor (SURI); Uricosuric Agents; Other Drugs
• 3) By Diseases: Gout; Kidney Stone; Other Diseases
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Companies Mentioned: Pfizer Inc.; Merck & Co.; Bayer AG; Sanofi SA; Myers Squibb Bristol Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hyperuricemia Drugs Market Characteristics

3. Hyperuricemia Drugs Market Trends And Strategies

4. Hyperuricemia Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Hyperuricemia Drugs Market Size and Growth

• 5.1. Global Hyperuricemia Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Hyperuricemia Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Hyperuricemia Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hyperuricemia Drugs Market Segmentation

• 6.1. Global Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Asymptomatic Hyperuricemia
• Symptomatic Hyperuricemia
• Other Types
• 6.2. Global Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs
• Xanthine Oxidase Inhibitors
• Selective Uric Acid Reabsorption Inhibitor (SURI)
• Uricosuric Agents
• Other Drugs
• 6.3. Global Hyperuricemia Drugs Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Gout
• Kidney Stone
• Other Diseases
• 6.4. Global Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users

7. Hyperuricemia Drugs Market Regional And Country Analysis

• 7.1. Global Hyperuricemia Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Hyperuricemia Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hyperuricemia Drugs Market

• 8.1. Asia-Pacific Hyperuricemia Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hyperuricemia Drugs Market

• 9.1. China Hyperuricemia Drugs Market Overview
• 9.2. China Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hyperuricemia Drugs Market

• 10.1. India Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hyperuricemia Drugs Market

• 11.1. Japan Hyperuricemia Drugs Market Overview
• 11.2. Japan Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hyperuricemia Drugs Market

• 12.1. Australia Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hyperuricemia Drugs Market

• 13.1. Indonesia Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hyperuricemia Drugs Market

• 14.1. South Korea Hyperuricemia Drugs Market Overview
• 14.2. South Korea Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hyperuricemia Drugs Market

• 15.1. Western Europe Hyperuricemia Drugs Market Overview
• 15.2. Western Europe Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hyperuricemia Drugs Market

• 16.1. UK Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hyperuricemia Drugs Market

• 17.1. Germany Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hyperuricemia Drugs Market

• 18.1. France Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hyperuricemia Drugs Market

• 19.1. Italy Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hyperuricemia Drugs Market

• 20.1. Spain Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hyperuricemia Drugs Market

• 21.1. Eastern Europe Hyperuricemia Drugs Market Overview
• 21.2. Eastern Europe Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hyperuricemia Drugs Market

• 22.1. Russia Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hyperuricemia Drugs Market

• 23.1. North America Hyperuricemia Drugs Market Overview
• 23.2. North America Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hyperuricemia Drugs Market

• 24.1. USA Hyperuricemia Drugs Market Overview
• 24.2. USA Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hyperuricemia Drugs Market

• 25.1. Canada Hyperuricemia Drugs Market Overview
• 25.2. Canada Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hyperuricemia Drugs Market

• 26.1. South America Hyperuricemia Drugs Market Overview
• 26.2. South America Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hyperuricemia Drugs Market

• 27.1. Brazil Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hyperuricemia Drugs Market

• 28.1. Middle East Hyperuricemia Drugs Market Overview
• 28.2. Middle East Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hyperuricemia Drugs Market

• 29.1. Africa Hyperuricemia Drugs Market Overview
• 29.2. Africa Hyperuricemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Hyperuricemia Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Hyperuricemia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hyperuricemia Drugs Market Competitive Landscape And Company Profiles

• 30.1. Hyperuricemia Drugs Market Competitive Landscape
• 30.2. Hyperuricemia Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bayer AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi SA
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Myers Squibb Bristol Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Hyperuricemia Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline PLC
• 31.4. Roche Holdings Inc.
• 31.5. Amgen Inc.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Teva Pharmaceuticals
• 31.8. Regeneron Pharmaceuticals Inc.
• 31.9. Teijin Pharma Limited
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Amneal Pharmaceuticals Inc.
• 31.14. Glenmark Pharmaceuticals Ltd.
• 31.15. Kissei Pharmaceutical Co. Ltd.

32. Global Hyperuricemia Drugs Market Competitive Benchmarking

33. Global Hyperuricemia Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Hyperuricemia Drugs Market

35. Hyperuricemia Drugs Market Future Outlook and Potential Analysis

• 35.1 Hyperuricemia Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Hyperuricemia Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Hyperuricemia Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer